Dapoxetine

Dapoxetine is the International Nonproprietary Nameof a drug currently being considered for approval by the FDAfor the treatment of premature ejaculationin men, which would make it the first drug approved for such treatment. It is currently in Phase III of the approval process. This would make it join the ranks of sildenafil(Viagra®), tadalafil(Cialis®), and vardenafil(Levitra®), the erectile dysfunctiondrugs, as a drug intended to improve male sexual health.

Dapoxetine, submitted to the FDA in the form of dapoxetine hydrochloride, was developed by ALZA Corporationand its parent company, Johnson & Johnson.javascript:insertTags('<math>','</math>','Insert formula here'); Mathematical formula (LaTeX)

Like other drugs in this category, it is controversial for turning something that is traditionally considered psychological into a physiologicalproblem that can be treated, to the benefit of the pharmaceutical industry (but also to the people with the dysfunction).

In October of 2005, the Food and Drug Administration issued a nonapprovable letter for Dapoxetine[1].

External links

• DapoxetineNews.com- News site
• Dapoxetine online- News site
• Press releaseby Ortho-McNeil, the company that will market dapoxetine in the USAif approved
• "The many mysteries of the female orgasm"- An editorial about advances in sexual pharmacology

This article is licensed under the GNU Free Documentation License.
It uses material from the http://en.wikipedia.org/wiki/Dapoxetine Wikipedia article Dapoxetine.